Firebrick Pharma (FRE.AX) Stock Price

Firebrick Pharma Price

ASX·CLOSED
0.03
​
Market closed

Revenue at Firebrick Pharma has contracted by 23.0% per year over the past 6 years to 106,029.00 AUD. For Firebrick Pharma, the net margin of -2,889.1% is up versus -92,054.1% a few years ago.

Firebrick Pharma stock price

Access this data via the Eulerpool API

Firebrick Pharma business model & stock analysis

Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is engaged in developing and commercializing a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The company also has a third patent family covering the Nasodine formulation. The company is completing two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results also be important for securing regulatory approvals and partnerships in markets outside Australia.

Frequently asked questions about Firebrick Pharma

Converted at the current exchange rate, the Firebrick Pharma share trades at 0.02 EUR (0.03 AUD).

The Firebrick Pharma share (FRE.AX) is listed on 1 stock exchanges, including: ASX (FRE.AX).

The revenue of Firebrick Pharma is 106,029.00 AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of Firebrick Pharma is -3.06 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Firebrick Pharma is currently -2.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Firebrick Pharma stock.

The price-to-sales ratio (P/S) of Firebrick Pharma is currently 71.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Firebrick Pharma stock.

The Eulerpool Quality Score for Firebrick Pharma is 3/10.

The ISIN of Firebrick Pharma is AU0000197352. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Firebrick Pharma is FRE.AX. The ticker symbol is used to trade Firebrick Pharma shares on the stock exchange.

Fair ValueTerminal
0.02 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Jan 28, 2022
ISIN
AU0000197352
Cusip
Q3917K103
Market capitalization
7.32 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
4.35
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-182.12 %
Last updated Oct 12, 2026, 11:25 AM

Firebrick Pharma Peer Group

Firebrick Pharma Ticker

ASX · FRE.AX

Firebrick Pharma FIGI

FRE:AU · BBG0140SS6L1FRE:AT · BBG0140SS6M0FRE:AH · BBG0140SS6R5